click on circles to display study description...
nivolumab plus SoC (n=179) vs. placebo plus SoC (n=179)
randomized controlled trial
nivolumab plus platinum doublet
nivolumab 360 mg plus histology-based platinum doublet chemotherapy every three weeks for up to three doses
placebo plus platinum doublet
placebo plus platinum doublet chemotherapy every three weeks for up to three doses, followed by surgery
locally advanced NSCLC - (neo)adjuvant (NA)
open label
P3
nivolumab plus SoC (n=177) vs. pemetrexed plus platin (n=186)
randomized controlled trial
nivolumab plus pemetrexed plus platine
nivolumab (3 mg per kilogram of body weight every 2 weeks)
platinum based chemotherapy (pemetrexed plus platine)
platinum doublet chemotherapy based on tumor histologic type every 3 weeks for up to four cycles : pemetrexed (500 mg per square meter of body-surface area) plus cisplatin (75 mg per square meter) or carboplatin (area under the concentration-time curve [AUC], 5 or 6), every3 weeks for up to four cycles.Crossover between treatment groups within the trial was not permitted.
3 arms: Nivolumab, or Nivolumab Plus Ipilimumab.Crossover between treatment groups within the trial was not permitted.
mNSCLC - L1 - PDL1 negative
Patients with known EGFR mutations or ALK translocations sensitive to targeted therapy, an autoimmune disease, or untreated central nervous system metastases were excluded.Tumor mutational burden was determined by the FoundationOne CDx assay,
open label
NA
P3/ two sided and one interim analysis. Repartition between coprimary end point and hierarchy with secondary endpoint
Progression-free survival was significantly longer with first-line nivolumab plus ipilimumab than with chemotherapy among patients with NSCLC and a high tumor mutational burden, irrespective of PD-L1 expression level.
powered by vis.js Network